Target intelligence / Profile preview

Hepatitis B virus large envelope protein PreS1 region (PreS1 (context: HBV L protein))

Target
PreS1 (context: HBV L protein)
Molecular classification
Viral envelope protein domain, Intrinsically disordered protein region, Membrane-interacting domain
01

Overview

The PreS1 region is an N-terminal domain of the large envelope (L) protein of hepatitis B virus that plays a pivotal role in the viral life cycle and pathogenesis. Composed of approximately 108–119 amino acids (depending on genotype), the PreS1 region is myristoylated at its N-terminus—a modification critical for its fusion and receptor-binding activities. The myristoylated PreS1 domain is exposed on the surface of mature HBV particles, where it directly binds the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, initiating viral entry. Additionally, hydrophobic regions within PreS1 facilitate membrane fusion, function as a fusion peptide, and mediate interactions with the viral capsid during virion maturation. These functions make PreS1 a major target for antiviral drugs and vaccine design, with small molecules and peptide mimics under development to block PreS1-mediated entry. Note: PreS1 itself is not a receptor, enzyme, or transporter, but a viral protein domain acting as a ligand for the human NTCP receptor and mediating membrane fusion, making its classification as a "therapeutic target" accurate in the context of HBV infection therapy.

Other names
PreS1 domainpre-S1 domainpre-S1 regionHBV PreS1L HBV PreS1 region
02

Mechanism of action

Competitive inhibition of PreS1 binding to NTCP, blocking viral entry to hepatocytes. Fusion inhibition (preventing membrane fusion and viral uptake).

03

Biological functions

Host cell receptor binding (specifically sodium taurocholate cotransporting polypeptide, NTCP)Membrane fusionVirion morphogenesis/viral assemblyCapsid-envelope interaction during virus maturation
04

Disease associations

Infection (critical for HBV hepatocyte entry)Chronic hepatitis B progressionHepatocellular carcinoma (due to persistent infection)
05

Safety considerations

Immune escape due to PreS1 sequence variabilityHepatocyte toxicity or immune-mediated liver damage (as PreS1 is linked to inflammation and carcinogenesis)Development of resistance to NTCP-targeting drugs
06

Interacting drugs

Entry inhibitors targeting NTCP–PreS1 interaction

1 more in the full profile.

07

Biomarkers

PreS1 antigen (for monitoring infectivity and therapeutic efficacy in HBV management)Anti-PreS1 antibody response (potential for therapy and monitoring)

Beyond the preview

Go deeper on Hepatitis B virus large envelope protein PreS1 region (PreS1 (context: HBV L protein)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis B virus large envelope protein PreS1 region (PreS1 (context: HBV L protein)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call